Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label daratumumab in previously treated AL amyloidosis
2016-000287-42Phase 2Completed
- Sponsor
- CHU de Limoges
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in light-chain amyloidosis, sponsored by CHU de Limoges. Primary endpoint: Overall hematologic response rate. Started Jun 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2016-000287-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000287-42.